Many healthcare workers on the front lines of the COVID-19 pandemic lack the needed patient-protective equipment, putting them at the highest risk of contracting the disease, Holly Kramer, MD, President of the National Kidney Foundation (NKF), said in a March 26 address to attendees of the organization’s first live-virtual Spring Clinical Meetings. “At no other…
Glecaprevir/pibrentasvir for 8 to 12 weeks is an effective and well-tolerated treatment for patients with chronic hepatitis C virus and chronic kidney disease stage 4 or 5.
The FDA has granted Fast Track designation for empagliflozin (Jardiance; Boehringer Ingelheim and Lilly) to reduce the risk of kidney disease progression and cardiovascular (CV) death in adults with chronic kidney disease.
The Centers for Disease Control and Prevention has updated the guidance for evaluation of persons under investigation for coronavirus disease 2019 (COVID-19), expanding the criteria to a wider group of symptomatic patients.
Study findings suggest the benefits of continuing ACEi or ARB therapy outweigh the risks in CKD patients with an eGFR less than 30 mL/min/1.73 m2.
People living in areas with higher levels of air pollution may be at higher risk of developing kidney disease.
World Kidney Day 2020 campaign focuses on prevention and detection of chronic kidney disease and equitable access to care.
The risk of CKD in patients with inflammatory bowel disease is highest among young individuals.
Women with hypertensive disorders of pregnancy not only appear to have elevated risks for cardiovascular and cerebrovascular disease, but also kidney disease.
Global CKD mortality increased 41.5% from 1990 to 2017, researchers reported.
